Louisiana Zantac Claims Attorneys

Author

Written on behalf of Lundy Lundy Soileau & South, LLP 
Louisiana Zantac Claims Attorneys

On April 1st, 2020, the U.S. Food and Drug Administration (FDA) made an announcement requesting the immediate withdrawal of prescription Zantac and over-the-counter ranitidine from the market. This action was taken as part of an ongoing investigation into a harmful substance called N-Nitrosodimethylamine (NDMA) found in ranitidine medications, commonly known and sold as Zantac.
​
The FDA has determined that certain impurities in ranitidine products can increase over time when stored at temperatures higher than room temperature, potentially leading to unacceptable levels of this impurity for consumers. As a result of this market withdrawal, ranitidine products are no longer available for new prescriptions, previous prescriptions, or over-the-counter use in the United States.

Based on information provided by third-party laboratories, the FDA conducted additional testing and evaluation, which confirmed that NDMA levels in ranitidine increase under normal storage conditions. Moreover, when exposed to temperatures higher than room temperature, NDMA levels were found to significantly rise. The FDA also expressed concerns about the temperatures that the product may be subjected to during transportation and handling by consumers. Furthermore, testing revealed that the older the product is, the higher the level of NDMA, surpassing the acceptable daily intake limit of NDMA.

Patients currently using prescription ranitidine should consult their physician to explore alternative treatment options before discontinuing the use of the medication.

There are several approved alternatives to ranitidine, such as cimetidine (Tagamet), famotidine (Pepcid), esomeprazole (Nexium), omeprazole (Prilosec), and lansoprazole (Prevacid), that do not carry the same NDMA-related risks. To date, the FDA's testing has not detected NDMA in these alternatives.

Lundy Lundy Soileau & South is actively investigating cases involving esophageal cancer, stomach/gastric cancer, bladder cancer, pancreatic cancer, and liver cancer associated with the use of Zantac. If you have received a cancer diagnosis after taking Zantac, please contact our attorneys at Lundy Lundy Soileau & South, Louisiana Zantac claims attorneys.

Types of Cancer Investigated:

• Bladder Cancer
• Stomach/Gastric Cancer
• Esophageal Cancer
• Liver Cancer
• Pancreatic Cancer

Tags & Related Pages

Louisiana Zantac Cancer Claims, Zantac Claims Texas, Mississippi, Arkansas, Oklahoma

Louisiana Zantac Claims Attorneys
Talcum Powder Claims Attorneys